Lee Ainslie Maverick Capital
Lee Ainslie is the founder of Maverick Capital, a long/short equity firm that emerged from the Tiger Management network of investors. Maverick is known for fundamental research, sector specialization among teams, and a classic hedge fund long/short structure. Ainslie’s firm remains a reference name among so-called Tiger Cub managers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EA
Electronic Arts
EA
|
+$96.5M |
| 2 |
GFL Environmental
GFL
|
+$92.9M |
| 3 |
QuidelOrtho
QDEL
|
+$79.1M |
| 4 |
Astera Labs
ALAB
|
+$73.9M |
| 5 |
Natera
NTRA
|
+$60.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coupang
CPNG
|
+$307M |
| 2 |
Constellation Brands
STZ
|
+$86.1M |
| 3 |
Domino's
DPZ
|
+$76.7M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
+$73.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$70.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 32.34% |
| 2 | Technology | 17.7% |
| 3 | Healthcare | 16.82% |
| 4 | Financials | 10.98% |
| 5 | Real Estate | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
B&G Foods
BGS
$281M
| – | – |
-106,317
| Closed | -$1.12M |
|
427
Biogen
BIIB
$32B
| – | – |
-1,600
| Closed | -$414K |
|
|
BNY
428
Bank of New York Mellon
BNY
$108B
| – | – |
-5,702
| Closed | -$297K |
|
429
Baker Hughes
BKR
$61.9B
| – | – |
-8,055
| Closed | -$275K |
|
430
Burlington
BURL
$20.6B
| – | – |
-6,492
| Closed | -$1.26M |
|
431
Citigroup
C
$221B
| – | – |
-7,369
| Closed | -$379K |
|
432
Credit Acceptance
CACC
$6.24B
| – | – |
-561
| Closed | -$299K |
|
433
Conagra Brands
CAG
$7.89B
| – | – |
-40,503
| Closed | -$1.16M |
|
434
CBRE Group
CBRE
$44B
| – | – |
-557,201
| Closed | -$51.9M |
|
435
Cracker Barrel
CBRL
$1.29B
| – | – |
-33,714
| Closed | -$2.6M |
|
436
Commercial Metals
CMC
$7.34B
| – | – |
-4,345
| Closed | -$217K |
|
437
Cinemark Holdings
CNK
$4.24B
| – | – |
-49,549
| Closed | -$698K |
|
438
Crane Co
CR
$12B
| – | – |
-1,849
| Closed | -$218K |
|
|
CRGX
439
DELISTED
CARGO Therapeutics
CRGX
| – | – |
-400,000
| Closed | -$9.26M |
|
440
CRH
CRH
$63.2B
| – | – |
-555,239
| Closed | -$38.4M |
|
441
Dominion Energy
D
$58.6B
| – | – |
-10,995
| Closed | -$517K |
|
442
Delta Air Lines
DAL
$54.2B
| – | – |
-21,977
| Closed | -$884K |
|
443
Dana Inc
DAN
$3.41B
| – | – |
-31,867
| Closed | -$466K |
|
444
Deutsche Bank
DB
$71.1B
| – | – |
-26,966
| Closed | -$365K |
|
445
Dollar General
DG
$27.2B
| – | – |
-14,527
| Closed | -$1.97M |
|
446
DraftKings
DKNG
$13B
| – | – |
-57,716
| Closed | -$2.03M |
|
447
Dick's Sporting Goods
DKS
$16.4B
| – | – |
-6,918
| Closed | -$1.02M |
|
448
Dollar Tree
DLTR
$25.3B
| – | – |
-6,662
| Closed | -$946K |
|
449
DexCom
DXCM
$34.8B
| – | – |
-4,876
| Closed | -$605K |
|
|
EHAB
450
DELISTED
Enhabit
EHAB
| – | – |
-14,828
| Closed | -$153K |
|
Similar funds
Lee Ainslie's Q1 2024 Portfolio in Review
As of Q1 2024, Lee Ainslie held 573 positions worth $5.32B, up 6.9% from $4.98B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Lee Ainslie withdrew a net $210M in Q1 2024, closing 168 positions and reducing 68 holdings. Its most notable exit was Immunogen Inc, an estimated $73.9M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 32% of assets, down from 36% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Lee Ainslie opened a new position in Electronic Arts worth $93.2M.
- Lee Ainslie's largest Q1 2024 buy was Electronic Arts: 702,830 shares worth $93.2M.
- Lee Ainslie added most to Starbucks in Q1 2024, an estimated $51.2M increase.
- Lee Ainslie's biggest Q1 2024 reduction was Coupang, cutting an estimated $307M.
- Lee Ainslie fully exited Immunogen Inc in Q1 2024, selling an estimated $73.9M.
- Lee Ainslie's ten largest holdings make up 45% of its $5.32B portfolio in Q1 2024.
- Lee Ainslie opened 225 new positions and closed 168 in Q1 2024.
- Lee Ainslie's portfolio value rose 6.9% quarter-over-quarter to $5.32B.
Based on Maverick Capital's 13F filing for Q1 2024, filed 15 May 2024.